Bob Rauker of Belluscura discusses their global manufacturing & US defence distribution agreements

Bob Rauker CEO of Belluscura #BELL discusses their transformational Global Manufacturing Agreement with Leading Asian Electronics Manufacturer and their Belluscura distribution and pricing agreement from the United States Defence Logistics Agency.

Highlights

Belluscura Enters into Transformational Global Manufacturing Agreement with Leading Asian Electronics Manufacturer

Affiliate of one of the world's leading electronics manufacturing companies to build the X-PLO2R® POC family of products in China allowing the Company to expand distribution into Asia

Belluscura plc, a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has today signed a manufacturing Master Supply Agreement ("MSA") with InnoMax Medical Technology, Ltd ("InnoMax") to manufacture the X-PLO2R® portable oxygen concentrator in the People's Republic of China. 

This agreement will more than double the Company's manufacturing capacity next year and enable us to accelerate our international expansion by opening up the Asian markets in 2023 and beyond.

InnoMax is a joint venture between MaxNerva Technology Services Limited (http://www.maxnerva.com/) and the National Center for the Advanced Medical Devices ("NMED") located in Shenzhen, China. NMED is the first national manufacturing innovation center in Shenzhen and is also the only innovation center set up by the Chinese government in the field of medical devices. Maxnerva Technology is an affiliate of one of the leading contract electronics manufacturers in the world. Commercialisation and distribution in Asia are expected to occur no later than Q1 2023. Belluscura plans to manufacture both the next generation X-PLO2R® oxygen concentrator and the next portable oxygen concentrator in its portfolio, the DISCOV-R™.

To read the full RNS click HERE

Belluscura is awarded a Distribution and Pricing Agreement ("DAPA") from the United States Defense Logistics Agency ("DLA") for the X-PLOR

Belluscura plc, a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the X-PLOR portable oxygen concentrator has been awarded a Distribution and Pricing Agreement ("DAPA") code from the U.S. Defense Logistics Agency ("DLA") through our distribution partner, Lovell Government Services Inc ("Lovell"). DLA procures items from manufacturers and suppliers and provides them to the Department of Defense and other federal/state customers throughout the US and globally. DLA procures more than $41.8 billion in goods and services annually on behalf of its customers.

Lovell is a Service-Disabled Veteran-Owned military purchasing organisation Small Business whose primary mission is to provide exclusive medical, surgical, and pharmaceutical resources to the U.S. Department of Defense and Veterans Affairs Medical Organizations. Lovell has already commenced selling the X-PLOR. 

To read the full RNS click HERE